30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

More 2010 Results: ProChon Biotech

* Focused on modulating fibroblast growth factor to create solutions for tissue regeneration
* Announced intent to merge with Histogenics, combine ProChon’s cell therapies with Histogenics’ tissue engineering platform
* In final stages of Phase II U.S. clinical trial for BioCart Cartilage Regeneration System; Phase III to begin in 2011 with 245-patient superiority study at up to 24 sites, endpoint 12 months
* Post-merger, plans to recapitalize via Series A round of financing, to raise $24MM